Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MDT vs AXNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MDT Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

MDT Overall Winner 6-Pillar Tally: MDT 6 – 0 AXNX Matrix Metrics: MDT 9 – 1 AXNX

As of Nov 20, 2026, Medtronic plc (MDT) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MDT carries a Unified Composite Score of 44.7/100 (HOLD) at $99.94 (16.5x Forward P/E, 20.1% operating margin), whereas AXNX carries 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. MDT 44.7/100 HOLD), MDT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (20.1% vs. N/A operating margin) and revenue trajectory (+13.7% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MDT vs AXNX
MDT NYSE Head-to-Head Winner
Medtronic plc
Electromedical & Electrotherapeutic Apparatus
$99.94
-0.67% 1D
Market Cap $128.7B
TTM Revenue $37.5B
Forward P/E 16.5x
Beta / 30D Vol 0.13β · 30% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 31.0 Fund 49.0 Flow 72.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 54
RSI-14: 53.7 · SMA20: $100.16 · SMA50: $94.63
AXNX US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
52.1 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (MDT 6 – 0 AXNX)

Columns: Metric · MDT · AXNX
1. Valuation Multiples MDT
Forward P/E 16.5x N/M
Trailing P/E 24.7x N/M
PEG Ratio 1.81x N/M
EV / Revenue 4.1x N/M
2. Growth & Scale MDT
Revenue Growth (YoY) +13.7% N/A
Earnings Growth (YoY) +40.7% N/A
TTM Revenue (USD) $37.5B N/A
Market Cap $128.7B N/A
3. Profitability & Quality MDT
Gross Margin 65.3% N/A
Operating Margin 20.1% N/A
Net Profit Margin 13.9% N/A
Return on Equity (ROE) 10.7% N/A
4. Balance Sheet & Cash Flow MDT
Cash Generation (TTM) $6.13B N/A
Cash Flow Margin 16.3% N/A
Net Cash / Leverage $26.5B Net Debt (0.56x D/E) N/A ROE
Dividend Yield 2.83% None (0.00%)
5. Options & Positioning MDT
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 34.6% (15th %ile) N/A (N/A)
Put/Call OI Skew 0.40x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MDT
OpEx & R&D Intensity 45.2% of Rev ($17.0B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MDT (9) vs AXNX (1)
Institutional Metric MDT AXNX Criterion Row Edge
Market Capitalization
Scale
$128.7B N/A Larger Scale MDT
Trailing P/E Ratio
Valuation
24.7x N/M Lower Multiple MDT
Forward P/E Ratio
Valuation
16.5x N/M Lower Multiple MDT
Revenue Growth (YoY)
Growth
+13.7% N/A Higher Growth MDT
Operating Margin (TTM)
Profitability
20.1% N/A Higher Margin MDT
Net Profit Margin
Profitability
13.9% N/A Higher Margin MDT
Return on Equity (ROE)
Capital Efficiency
10.7% N/A Higher ROE MDT
52-Week Range Position
Momentum
81% ($73–$106) 50% ($0–$1) Stronger Trend MDT
Beta / 30D Volatility
Risk Regime
0.13β · 30% Vol N/A Lower Realized Risk MDT
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite AXNX
Trailing 12M Revenue (USD)
Operating Scale
$37.5B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.81x PEG · 4.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$6.13B ($26.5B Net Debt (0.56x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MDT +30.01 pp
MDT: +3.47% · AXNX: -26.54%
3M Horizon AXNX +9.47 pp
MDT: +7.45% · AXNX: +16.92%
6M Horizon AXNX +9.47 pp
MDT: +7.45% · AXNX: +16.92%
1Y Horizon AXNX +9.47 pp
MDT: +7.45% · AXNX: +16.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDT vs AXNX. Trailing 12-month operating profitability (MDT 20.1% vs AXNX N/A) and valuation multiples (MDT 16.5x vs AXNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MDT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$37.5B
Gross Margin65.3%
Op. Margin20.1%
ROE / Fwd P/E10.7% · 16.5x
AXNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MDT CONSOLIDATION
66d in phase · OBV DISTRIBUTION
Current IV 34.6%
IV Percentile 15th %ile
Put/Call OI Skew 0.40x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AXNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AXNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $102.88 · IV 30.4%

MDT Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($10,288)

Compare $10,288 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 30.4% ATM IV.

5-DAY BULLISH SWING Liq A

Nov 27 $103 / $106 Bull Call Spread

Buy 1x $103C · Sell 1x $106C · 10d

Net Entry $126 Debit
T+5d @ +5% Move +$109 (+86%)
Max Risk / Buffer $126 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $97.5 / $90 Bull Put Spread

Sell 1x $97.5P · Buy 1x $90P · 31d

Net Entry $93 Credit
Max Credit / Yield +$93 (+14.2% RoM)
Max Risk / Buffer -6.1% Cushion ($657 Mgn)
5d Edge & Liquidity 76% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Asymmetric 1x1x1 ($105C + $101/$95P)

+1x 17d $101P · -1x 59d $95P · +1x 31d $105C

Net Entry $322 Debit
T+5d @ +5% Move +$190 (+10.9% RoM)
Max Risk / Buffer -7.7% Put Cushion ($1,744 Mgn)
5d Edge & Liquidity 2.5x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MDT Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $128.7B market capitalization and 20.1% operating margin.
OpEx & R&D Reinvestment 45.2% of Rev ($17.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
AXNX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MDT vs AXNX Key Questions & Quantitative Answers

As of Nov 20, 2026, Medtronic plc (MDT) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MDT carries a Unified Composite Score of 44.7/100 (HOLD) at $99.94 (16.5x Forward P/E, 20.1% operating margin), whereas AXNX carries 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. MDT 44.7/100 HOLD), MDT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (20.1% vs. N/A operating margin) and revenue trajectory (+13.7% vs. N/A YoY).

MDT leads the Growth & Scale pillar: MDT posts +13.7% YoY revenue growth and +40.7% YoY earnings growth on $37.5B TTM revenue (65.3% gross margin, 20.1% operating margin), compared with AXNX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, MDT generates $37.5B in USD-normalized revenue versus N/A for AXNX. In operating R&D and SG&A reinvestment, MDT deploys 45.2% of Rev ($17.0B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AXNX.

MDT screens cheaper on headline valuation multiples. MDT trades at 16.5x Forward P/E, 24.7x Trailing P/E, 1.81x PEG, and 4.1x EV/Revenue (16.3% FCF margin), whereas AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MDT (10.7% ROE) versus AXNX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, MDT carries 34.6% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.40x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.13β · 30% Vol realized risk). By comparison, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.